Source comparison
PT-141 Animal Research: Study Type Comparison
Male Rats (Sprague-Dawley) Spontaneous erections, mounting frequency, intromission latency 0.5–2.5 mg/kg SC 70% showed spontaneous erections at 1.0 mg/kg; effect blocked by MC4R antagonists Minimal. BP increase <10 mmHg Gold standard for behavioral pharmacolog
This comparison does not assign a generated winner or score.
- Male Rats (Sprague-Dawley)
- Spontaneous erections, mounting frequency, intromission latency
- 0.5–2.5 mg/kg SC
- 70% showed spontaneous erections at 1.0 mg/kg; effect blocked by MC4R antagonists
- Minimal. BP increase <10 mmHg
- Gold standard for behavioral pharmacology; dose-response well-characterized
- Female Rats (Ovariectomized)
- Lordosis quotient, receptivity behaviors, approach latency
- 0.75–2.0 mg/kg SC
- Behavioral effects present only with concurrent estrogen replacement
- Not assessed in female models
- Demonstrated estrogen-dependence of arousal response
- Canine Models (Beagle)
- Blood pressure, heart rate, erectile tumescence
- 0.05–0.2 mg/kg SC
- Mean arterial pressure +15–20 mmHg; transient hypertension resolved within 6 hours
- Significant. Hypertensive episodes at all doses
- Informed human trial exclusion criteria for cardiovascular disease
- Cynomolgus Macaques
- Cardiovascular endpoints, repeated-dose tolerance, behavioral arousal
- 0.1–0.3 mg/kg SC
- Transient BP elevation without tolerance over 4 weeks; no sustained hypertension
- Moderate. +12–18 mmHg systolic, resolved by 6 hours
- Closest physiological model to humans; demonstrated safety of repeated dosing
- MC4R Knockout Mice
- Behavioral response to PT-141, receptor specificity validation
- 1.0 mg/kg SC
- Complete loss of arousal and anorexigenic effects; confirmed MC4R as primary target
- Not assessed
- Definitive proof of mechanism; eliminated alternative pathway hypotheses